Literature DB >> 10542106

32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

D Pluim1, M Maliepaard, R C van Waardenburg, J H Beijnen, J H Schellens.   

Abstract

To allow more sensitive, selective, and routine analyses of platinum(Pt)-GG and -AG intrastrand cross-links we have significantly improved our quantitative (32)P-postlabeling assay (M. J. P. Welters et al. Carcinogenesis 18, 1767-1774, 1997). Instead of off-line scintillation counting we introduced an on-line flow radioisotope detector into the HPLC system. Furthermore, the isolation protocol for the adducts was significantly modified and optimized to reduce interfering background peaks that prevented quantification of low levels of the cisplatin-DNA adducts in white blood cells obtained from patients. Reduction of background signals was obtained by boiling the samples, followed by phenol/chloroform/isoamylethanol extraction after the DNA digestion step. The labeling efficiency for the adducts was increased by 40% by using Na-formate instead of NH(4)-formate for elution of the adducts from the strong cation-exchange columns. Finally, a calibration curve and quality controls were implemented. The labeling efficiencies were not different between the dinucleotides. The between- and within-run precision for the Pt-GG and Pt-AG adducts measured at the lower limit of quantification of 87 and 53 amol/microg DNA, respectively, was less than 20% CV. The adducts were stable in DNA stored for a 2-month time period at -80 degrees C. The assay is now routinely used for high-precision analyses of patient and cell line samples containing very low adduct levels. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10542106     DOI: 10.1006/abio.1999.4302

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  7 in total

1.  Development of an ultraperformance liquid chromatography/mass spectrometry method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts.

Authors:  Irene M Baskerville-Abraham; Gunnar Boysen; J Mitchell Troutman; Esra Mutlu; Leonard Collins; Kathryn E Dekrafft; Wenbin Lin; Candice King; Stephen G Chaney; James A Swenberg
Journal:  Chem Res Toxicol       Date:  2009-05       Impact factor: 3.739

Review 2.  Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.

Authors:  George D Cimino; Chong-xian Pan; Paul T Henderson
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

3.  Nuclease digestion and mass spectrometric characterization of oligodeoxyribonucleotides containing 1,2-GpG, 1,2-ApG, and 1,3-GpXpG cisplatin intrastrand cross-links.

Authors:  Renee T Williams; Jenifer N Nalbandian; Audrey Tu; Yinsheng Wang
Journal:  Clin Chim Acta       Date:  2012-12-22       Impact factor: 3.786

4.  Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.

Authors:  Bernd Liedert; Dick Pluim; Jan Schellens; Jürgen Thomale
Journal:  Nucleic Acids Res       Date:  2006-03-29       Impact factor: 16.971

5.  Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.

Authors:  W S Siegel-Lakhai; M Crul; S Zhang; R W Sparidans; D Pluim; A Howes; B Solanki; J H Beijnen; J H M Schellens
Journal:  Br J Cancer       Date:  2005-11-28       Impact factor: 7.640

6.  Long-term platinum retention after treatment with cisplatin and oxaliplatin.

Authors:  Elke E M Brouwers; Alwin D R Huitema; Jos H Beijnen; Jan H M Schellens
Journal:  BMC Clin Pharmacol       Date:  2008-09-17

7.  Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.

Authors:  F J P Hoebers; D Pluim; A A M Hart; M Verheij; A J M Balm; G Fons; C R N Rasch; J H M Schellens; L J A Stalpers; H Bartelink; A C Begg
Journal:  Cancer Chemother Pharmacol       Date:  2007-07-18       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.